MD, CSPQCHU de Québec - Université Laval - L'Hôtel-Dieu de Québec
Dr Yves Fradet graduated from Laval University (Quebec, Canada) in 1981 and completed an oncology fellowship at the Memorial Sloan-Kettering Cancer Center, with Drs Willet Whitmore and Lloyd Old. In 1983 he founded, at the Laval University Cancer Research Center, a translational and clinical research laboratory in urological cancers whose work are supported continuously for more than 30 years.
Dr Fradet still has a very active practice in uro-Oncology; he is Director of the Urologic Oncology Section and the Urology Service at the CHU de Québec- Hôtel-Dieu de Québec where he has grouped a team of specialists among the most important in Canada including seven uro-oncologists, two of which are also holders of PhD.
He is a member of many national and international societies, including since 2001, the American Association of Genitourinary Surgeons in which he was invited to be part of the 75 members in America. More recently, he was appointed international Honorary member of the Association of Academic European Urology, membership awarded to those who have had important influence on urology. Dr Fradet is often invited as a guest speaker at national and international meetings, as a visiting professor, and as a consultant to many organizations. He was the founding chairman of the Canadian Urologic Oncology Group from 1988 to 1995 and chairman of the Department of Surgery at Laval University from 2000 to 2008. He has authored over 315 publications and book chapters and 508 abstracts.
Dr Fradet is the recipient of numerous honours, including the "Life achievement award" from the Quebec Urological Association, Canadian Urological Association and the Société Internationale d’urologie as well as the Queen’s Diamand Jubilee Medal from the Canadian Medical Association as a pioneer in advanced tumor immunology research. He also founded in Quebec, in 1995, the company DiagnoCure of which he is president and Chief of Medical Affairs. Diagnocure has developed and marketed diagnostic tests for bladder, prostate and colon cancers. His achievements have earned him the “innovation award” of the Association for the development of research and innovation in Quebec (ADRIQ) and the price Friesen-Rygiel which was presented to him by the Canadian Nobel Prize Michael Smith, then Chairman of the selection Committee.
Dr Fradet's research activities involve translational laboratory research in tumour immunology and molecular biology, the genetics of bladder and prostate cancer and their applications to new diagnostics and treatments, epidemiological studies in bladder and prostate cancers, and clinical trials in prostate cancer and other genitourinary cancers.